Quick Answer
Arcutis Biotherapeutics, Inc. reported Stockholders Equity of $189.48 million for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +20.3% in Stockholders Equity from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$30.54 million | Q2 2019: -$38.66 million | Q3 2019: -$52.95 million | Q1 2020: $241.88 million | Q2 2020: $208.92 million | Q3 2020: $173.07 million | Q1 2021: $450.99 million | Q2 2021: $414.49 million | Q3 2021: $363.00 million | Q1 2022: $253.77 million | Q2 2022: $195.38 million | Q3 2022: $270.77 million | Q1 2023: $139.73 million | Q2 2023: $80.51 million | Q3 2023: $46.72 million | Q1 2024: $224.94 million | Q2 2024: $186.43 million | Q3 2024: $156.64 million | Q1 2025: $142.66 million | Q2 2025: $138.97 million | Q3 2025: $158.07 million.
- Over the full 9 years of available data (2017 to 2025), Arcutis Biotherapeutics, Inc.'s Stockholders Equity has grown by 3,894.9%.
- Historical annual values: Fiscal year 2025: $189.48 million | Fiscal year 2024: $157.54 million | Fiscal year 2023: $88.67 million | Fiscal year 2022: $209.58 million | Fiscal year 2021: $297.68 million | Fiscal year 2020: $270.62 million | Fiscal year 2019: -$65.03 million | Fiscal year 2018: -$23.99 million | Fiscal year 2017: -$4.99 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: